Skip to content

Novartis, Roche back French gene therapy startup Vivet

May 5, 2017

French gene therapy start-up Vivet Therapeutics said on Thursday it had raised 37.5 million euros ($41 million) in an initial financing round, with backing from the venture arms of Swiss drugmakers Novartis and Roche.

Other investors include Columbus Venture Partners, HealthCap, Kurma Partners and Ysios Capital.

Vivet, created last year in Paris with a wholly owned subsidiary in Spain, is focused on developing novel gene therapies for rare, inherited metabolic diseases.

Its lead program VTX801, which is expected to enter clinical testing by the end of 2018, targets a condition called Wilson disease caused by a defective gene in liver cells that can require liver transplantation and is sometimes fatal.

Vivet has developed a next-generation AAV gene therapy technology designed to increase gene expression levels in the liver, while reducing the risk of undesirable immune system effects.

Gene therapy seeks to cure rare genetic diseases by offering a one-time fix of a faulty DNA. There is rising interest in the field, even though the Western world’s first gene therapy for an ultra-rare condition is being pulled from the market due to lack demand.

http://reut.rs/2pLeUNc

Advertisements

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: